Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

Presentation ESC 2025

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Presenter: Subodh Verma

September 01, 2025

News Daily News

Carbon Footprint of Surgical AVR Double the Size of TAVI’s

Yael L. Maxwell

July 15, 2025

News Conference News AHA 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Michael O'Riordan

November 17, 2024

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Todd Neale

June 26, 2024

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Shelley Wood

August 25, 2023

News Daily News

CABG and PCI Comparable in ACS Patients With Left Main CAD

Michael O'Riordan

June 06, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News AHA 2021

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Michael O'Riordan

November 15, 2021

News Conference News AHA 2021

PALACS: Posterior Left Pericardiotomy Cuts Postop AF After Cardiac Surgery

Todd Neale

November 14, 2021

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Conference News AHA 2020

High Burden of Post-CABG A-fib After Hospital Discharge: SEARCH-AF

Michael O'Riordan

November 16, 2020

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

Caitlin E. Cox

May 15, 2020

News Conference News AHA 2019

No Benefit of Colchicine in All-Comers PCI

Shelley Wood

November 17, 2019

News Daily News

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Michael O'Riordan

October 17, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Daily News

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

Caitlin E. Cox

August 27, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

Advertisement

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Carbon Footprint of Surgical AVR Double the Size of TAVI’s

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Will Semaglutide Change Cardiac Surgery? It Already Has

Semaglutide Has Similar Benefits in Women and Men With HFpEF

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

CABG and PCI Comparable in ACS Patients With Left Main CAD

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

PALACS: Posterior Left Pericardiotomy Cuts Postop AF After Cardiac Surgery

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

High Burden of Post-CABG A-fib After Hospital Discharge: SEARCH-AF

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

No Benefit of Colchicine in All-Comers PCI

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content